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doi:10.1016/j.hkpj.2011.06.004Abstract Glucosamine (GlcN) is a popular nutritional supplement/prescription for relieving
symptoms of osteoarthritis (OA), particularly for the knee joint. Although there are certain
studies reporting the positive effects of GlcN for OA, its use remains controversial and the
mechanism behind is unclear. This article critically reviewed published papers on the effects
of GlcN in human clinical trials and animal studies. Twelve human clinical studies were re-
viewed and half of the studies reported positive effects of GlcN for OA or regular knee pain.
Eight animal studies were reviewed and most of them had involved histological examination
of cartilage, glycosaminoglycan content, subchondral bone, and synovium. Besides, nocicep-
tive behaviour, biochemical markers, and immunohistochemistry of the joints were also exam-
ined. There is some evidence showing the beneficial effects of GlcN on joint structural repair in
animals, but further research is needed to confirm the applicability of these models in human.
Copyright ª 2011, Elsevier. All rights reserved.IntroductionOsteoarthritis
Osteoarthritis (OA) is the most common joint disorder
affecting elderly people. According to the report from the
World Health Organisation, OA is the 6th leading cause of
nonfatal burden in the world in the new millennium. The
most frequently affected joints are the hands, knees, and
hips [1]. Most studies of OA have focused on the change oft of Rehabilitation Sciences,
, Hung Hom, Kowloon, Hong
k (G.Y.F. Ng).
ight ª 2011, Elsevier. All rights recartilage, but OA is not solely a disorder of the articular
cartilage, other components of the joint such as the sub-
chondral bone [2,3], synovial lining [4], ligaments, and
periarticular muscles [5] are also affected. The symptoms
are often associated with inflammation; which include
pain, stiffness, and loss of mobility thus resulting in func-
tional impairment [6]. The condition is not reversible and
has few effective medical remedies [1].Glucosamine
Glucosamine (GlcN) has been the focus of research for
relieving symptoms of OA for the last two decades with
most of the studies focussing on the knee joint. Glucos-
amine (2-amino-2-deoxyalpha-D-glucose) is a naturally
occurring amino monosaccharide comprising a glucoseserved.
43molecule attached to an amino group and present in the
matrix of all connective tissues. The human body can
naturally synthesize GlcN by means of the hexosamine
pathway by combining glutamine with fructose [7]. GlcN is
one of the principal substrates used in the biosynthesis of
hyaluronan, chondroitin, dermatan, keratin, glycosamino-
glycans, and proteoglycans and all of which are funda-
mental components of the extracellular matrix of articular
cartilage [7]. Therefore, the notion of GlcN in relieving the
symptoms of OA is based on the assumptions that abundant
administration of the precursors of extracellular matrix
components would help chondrocytes to proliferate and
replace the degenerated cartilage.
The half-lives of the metabolic turnover of cartilage
proteoglycans were measured in days in younger animals
and months in elder animals [8], thus cartilage is believed
to be continually rebuilding itself [9,10]. Oral consumption
of GlcN is thought to augment the endogenous production
of GlcN as well as proteoglycan and hence maintain
a normal turnover of the cartilage [11]. Furthermore,
recent studies have proposed that the efficacy of GlcN may
be because of its anti-inflammatory and anti-catabolic
properties [12,13].
The Osteoarthritis Research Society International
(OARSI) has recommended GlcN as a symptom-relieving and
structure-modifying agent for knee OA [14]. Oral GlcN is
widely used for modulating pain associated with OA. It can
come in combination with other supplements such as
chondroitin or by itself in the form of GlcN hydrochloride or
GlcN sulphate. The recommended dosage is 1500 mg/d
(20 mg/kg in a 75 kg subject) or 500 mg three times a day,
which can ensure plasma concentrations of 10mM of GlcN
[15], but without recognizable pattern of adverse effects
[16e19].
Although GlcN is a popular nutritional supplement/
prescription around the world, its efficacy is uncertain.
There are three meta-analyses critiquing the efficacy of
GlcN and advocating the benefits of GlcN on OA [20e22].
However, cautions should be paid on the interpretation of
the results as some studies had suffered from methodo-
logical problems such as inadequate allocation conceal-
ment and absence of intent-to-treat approaches, which
might have overestimated the actual benefits of GlcN [20].
Towheed et al [22] showed that GlcN prepared by Rotta
Pharmaceuticals (Eatontown, NJ, USA) was superior to
placebo in the treatment of pain and functional impairment
resulting from OA. Contrary to those reports, a recent
meta-analysis has concluded that GlcN could neither
reduce joint pain nor increase joint space [23]. The use of
GlcN to treat OA remains controversial and the mechanism
behind is unclear. Therefore, this article aimed to critically
review articles of GlcN on OA, with focus in the knee joint,
in both human clinical trials and animal studies.
Human clinical studies
A Medline search was performed in February 2011 for the
years 2000e2010 using the key words “glucosamine”,
“human clinical trials”, “OA”, and “knee” to screen all
citations that involved GlcN in the management of knee OA
or knee pain. Studies that compared GlcN-only preparationswith placebo and double-blind, placebo controlled
randomized clinical trials were deemed appropriate. With
the above criteria, 12 studies were identified to fit in the
criteria and were included for this review (Tables 1e4).
Baseline characteristics of participants
To have meaningful comparisons between treatment
groups, the patient characteristics should be similar at
baseline. Nevertheless, the baseline characteristics of
patients were significantly different between the groups in
two of the reports [24,25]. In McAlindon’s [25] study, the
placebo group had more female participants, used more
nonsteroidal anti-inflammatory drug, and had higher body
mass index than the GlcN group at baseline. Higher body
mass index has been reported to associate with increase in
physician- and patient-assessed levels of pain [26], which
might affect the outcome measure. In Cibere’s [24] study,
more female participants and less severity in OA were
found in the placebo group.
Gender difference among the participants
In most of the studies, women had accounted for more than
50% of the subjects ranging from 56.5% to 87.4%. The
exceptions were Braham’s [10] and Rindon’s [27] studies in
which the proportion of women was 28.3% and 5.1% corre-
spondingly (Table 1). Women, particularly, those aged 55
years or above have a higher risk of developing knee OA,
and more functional disabilities than men [28]. The gender
difference of coping with knee OA should also be consid-
ered. Men and women adopt different gait strategies to
reduce pain and to cope with the loads acting on the
affected joints [29]. Women having OA reported more
severe pain and physical disability [30]. Because the
common clinical outcome measures of OA are self-reported
pain and functional scales, it is possible that gender
difference in perception of pain may affect the scores in
the outcome measures.
Medication used during the experimental period
Because nonsteroidal anti-inflammatory drugs and analge-
sics would provide significantly greater pain relief than
placebo [31], continuous use of these mediations during the
experimental period may mask the efficacy of GlcN. Two of
the studies reviewed did not encourage the use of rescue
medication [10,32] and hence less than 9% of participants in
these studies had consumed rescue medication (Table 2).
For the study of Braham et al [10], it also set a washout
period of 1 week before the assessment date.
In the study of McAlindon et al [25], the amount of
rescue medication use was a secondary outcome measure,
but this outcome measure is questionable because signifi-
cant difference between groups was found at baseline
measurement. In the study of Herrero-Beaumont et al [33],
there were significantly less subjects completing the study
using rescue medication in the GlcN group. Other studies
which demonstrated GlcN to be more effective over
placebo had set washout periods ranging from 1 week to 2
Table 1 Baseline characteristics of participants
Study No. of
subjects
(groups)
% of female
participants
Mean age Mean BMI History of
OA/knee
pain (yr)
Severity of OA/knee pain Duration
of treatment
Braham et al [10] 46 (2) 28 43 Not shown median >10 Pain section of KOOS score 55 12 wk
Sawitzke et al [19] 662 (5) 68 57 w50% of subjects
had BMI >30
10 KL score 2e3 24 mo
Cibere et al [24] 137 (2) 57 (placebo vs.
GlcN, p < 0.05)
64 27.5 3 KL score 2e4 (placebo vs. GlcN,
p < 0.05)
6 mo
McAlindon, T [25] 186 (2) 64 (placebo vs.
GlcN, p Z 0.04)
45e95, median
55e64
31 in GLcN,
34.1 in placebo,
p Z 0.01
Not shown 84% of participants with severe
OA (total joint space loss)
12 wk
Rindone et al [27] 98 (2) 5 64 Not shown 13 KL score 1e4 2 mo
Petersen et al [32] 36 (3) 60 62.4 27.8 Not shown KL score 1e4 12 wk
Herrero-Beaumont [33] 318 (3) 88 64 27.7 7 KL score 2e3 6 mo
Reginster et al [34] 212 (2) 76 66 27.4 7.9 KL score 2e3 3 yr
Usha & Naidu [35] 118 (4) 64 51 Not shown 3 Lequesne index 8e18 12 wk
Clegg et al [36] 1583 (5) 64 59 31.7 9.5e10.4 KL score 2e3 24 wk
Hughes & Carr [37] 80 (2) 68 62 Not shown 7.62 KL score 1e4 6 mo
Pavelka et al [38] 202 (2) 78 62.4 25.7 10.5 KL score 2e3 3 yr
KOOS, consists of 5 sections namely pain, symptoms, activities of daily living, sport/recreation, and knee related quality of life. It ranges from 0 to 80 with higher scores representing lower
pain levels KL, ranges from 0 to 4, with 0 being normal and 4 being severe OA Leguesne index: OA specific questionnaire addressing pain, function limitation and ability to walk. It ranges
from 0 to 24 with higher score indicating more severe of OA.
BMI Z body mass index; GlcN Z Glucosamine; KL Z Kellgren and Lawrence radiographic grading scale; KOOS Z Knee injury and osteoarthritis outcome score; OA Z osteoarthritis.
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Table 2 Medication used
Study % of subjects taking rescue
medications at baseline
% of subjects taking
medication during the
study period
Mean quantity of
medication used
Washout period
before assessment
Difference between groups
At baseline During treatment
Braham et al [10] Not shown 8.7% (6.5% in placebo,
2.2% in GlcN)
Not shown 1 wk Not shown
Sawitzke et al [19] Washout period before
baseline
Not shown 570 mg of paracetamol
daily
24 hr No Not shown
Cibere et al [24] 68% in GlcN, 73%in placebo
(acetaminophen and
NSAID)
72% in GlcN, 76%
in placebo
Not shown No No No
McAlindon, T [25] 74% in GlcN, 87% in
placebo, p Z 0.03 (NSAID)
Not shown Not shown Not described Significantly less
subjects used
NSAID in GlcN
No
Rindone et al [27] 28% (NSAID,
acetaminophen,
hydrocodone)
Not shown Not shown Not described No Not shown
Petersen et al [32] 33.3% (NSAID) 8.6% (5.7% in placebo,
2.9% in ibuprofen)
50 mg of tramadol for
less than 5 d
Not described Not shown
Herrero-Beaumont [33] Washout period before
baseline
91% in placebo, 78%
in GlcN
0.2e0.26 tablets of
400 mg ibuprofen daily
1 wk No Significantly less
subjects used
ibuprofen in GlcN
Reginster et al [34] 49% (NSAID, analgesics,
corticosteroids)
50% Less than 1 dose of
rescue drug every 6 d
5 half-lives No No
Usha & Naidu [35] Washout period before
baseline
Not shown 30e95 tablets of
500 mg paracetamol
2 wk No Significantly less
subjects used
paracetamol in
combination of GlcN
and MSM groups
Clegg et al [36] Not shown Not shown 1.6e1.9 tablets of
400 mg acetaminophen
daily
24 hr No No
Hughes & Carr [37] 22.5% analgesics, 46%
NSAIDs
Not shown 43 tablets of
paracetamol in GlcN,
45 in placebo
Not described No No
Pavelka et al [38] Not shown 30e40% in both groups 500 mg Acetaminophen
every 3 d
Not described No No
GlcN Z Glucosamine; MSM Z Methylsulfonylmethane; NSAID Z nonsteroidal anti-inflammatory drug.
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Table 3 Form of glucosamine
Study Dosage (mg/d) Form
of GlcN
Supplier of GlcN Selection criteria of GlcN
use at baseline
Braham et al [10] 2000 HCl Not shown Not shown
Sawitzke et al [19] 1500 HCl Not shown Not shown
Cibere et al [24] Equivalent to
the dosage of GlcN
intake before, max:
1500
SO4 Vita health (dietary supplement) Present daily-user
for >1 mo
McAlindon, [25] 1500 SO4 Physiologics (initial supplier) Present users excluded
Rotta Pharmaceuticals (prescription drug)
(Subsequent supplier)
Rindone et al [27] 1500 SO4 Applehart Laboratories Past and present users
excluded
Petersen et al [32] 1500 SO4 Ferrosan Washout period: 1 mo
Herrero-Beaumont [33] 1500 SO4 Rotta Pharmaceuticals (prescription drug) Washout period: 6 mo
Reginster et al [34] 1500 SO4 Rotta Pharmaceuticals (prescription drug) Not shown
Usha & Naidu [35] 1500 SO4 Healers Limited Not shown
Clegg et al [36] 1500 HCl Ferro Pfanstiehl Laboratories Not shown
Hughes & Carr [37] 1500 SO4 Health Perception (dietary supplement) Not shown
Pavelka et al [38] 1500 SO4 Rotta Pharmaceuticals (prescription drug) Not shown
46 K.O.W. Chan, G.Y.F. Ngweeks or 5 half-lives of the drug before symptom assess-
ment [10,33e35].
History of glucosamine used
Among the articles reviewed, seven did not mention
whether the participants had used GlcN before baseline
measurement [10,19,34e38] (Table 3). Two had excluded
present users of GlcN [25,27] and two others had set
washout period for subjects with histories of GlcN
consumption [32,33]. Based on the data from a long-term
study [38], the change of Lequesne index after GlcN
consumption was greater in the first year. Because GlcN has
become popular and easily available, it is difficult to recruit
subjects who have never consumed this substance before.
Furthermore, there may also be carryover effect with GlcN
consumption [39], which is not well reported and it should
be further investigated.
Quality control of glucosamine preparation
The classification of GlcN is different among countries.
Although it is a prescription in all European Union countries,
it is classified as a dietary supplement in the USA [40].
Substances in the class of dietary supplement are usually
under less stringent control when compared with
prescriptions [41]. Among the 12 studies, 4 had used
registered drug [25,32e34,38], 2 had used dietary supple-
ment [24,37] and the others had used unknown sources of
GlcN (Table 3). Most of the studies did not describe the
quality control on the composition of GlcN. Based on
a study assessing the content of active ingredient in over-
the-counter GlcN sulphate preparations, it has revealed
that the amount of active ingredient varied from 41% to
108% when compared with the content stated on the label
[42]. The large discrepancy in the claimed compositions andactual content of the GlcN preparations would affect the
analysis of the efficacy of GlcN.
Towheed et al [22] and Vlad et al [43] suggested that
GlcN prepared by Rotta Pharmaceuticals was superior to
placebo in the treatment of pain and functional impairment
resulting from symptomatic OA. The effect size for trials
using the Rotta pharmaceuticals preparation was much
higher than that of other preparations (ES: 0.55 vs. 0.11)
[43]. Although the GlcN manufactured by Rotta Pharma-
ceuticals is under the category of pharmaceuticals/
prescription drug, this might explain the superiority of this
GlcN preparation to the placebo group [33,34,38].
Forms of glucosamine
The common form of GlcN includes GlcN sulphate and GlcN
hydrochloride. Only three of the reviewed studies had used
the hydrochloride form (Table 3). One of them showed
pain relief and improvement in knee related quality of life
[10], whereas another showed decreased in OA-related
pain level [Western Ontario and McMaster Universities
(WOMAC) OA pain score 301e400] when GlcN was
consumed with chondroitin sulphate [36]. Early hypothesis
suggested that a component of the activity of GlcN
sulphate was related to the sulphate residues in the
compound as sulphur is an essential nutrient for stabilizing
the extracellular matrices of connective tissue [7]. Vlad
et al [43] also concluded that GlcN hydrochloride had no
effect on pain as the effect size of GlcN hydrochloride was
much smaller than that of GlcN sulphate. However, Ver-
bruggen [44] found that the preparation used in many
studies were two single molecules of GlcN and sulphate
instead of a GlcN sulphate ester, therefore the active
ingredient should be GlcN. Block et al [15] also rejected
the hypothesis that increasing sulfate anion supply could
boost the synthesis of the tissue matrix, because the
concentration of serum sulfate after consumption of
Table 4 Outcome measures of human trials
Study Efficacy WOMAC pain,
stiffness and
function
Lequesne
index
OMERACT/
OARSI
Joint space
narrowing
Others
Braham et al [10] Yes N/A N/A N/A N/A (Knee Pain Scale, p Z 0.004;
knee related quality of life,
p Z 0.038)a
Sawitzke et al [19] No NS (pain,
p Z 0.97,
function,
p Z 0.56)
N/A NS (p > 0.05) N/A
Cibere et al [24] No NS (total score,
p Z 0.96)
N/A N/A N/A NS (EQ-5D questionnaire and
disease flare, p > 0.05)
McAlindon, T [25] No NS (total score,
p Z 0.81)
N/A N/A N/A NS (use of rescue medications,
p Z 0.12)
Rindone et al [27] No N/A N/A N/A N/A NS (Visual analogue scale of
pain at rest and during walking,
p Z 0.66e0.90, NS)
Petersen et al [32] Yes N/A N/A N/A N/A (Serum COMP, p Z 0.0378), NS
(Urinary CTX-II, p Z 0.1)a
Herrero-Beaumont [33] Yes (p Z 0.018)a (p Z 0.01)a N/A N/A (Use of rescue medications,
p Z 0.027)a
Reginster et al [34] Yes (p Z 0.016)a N/A N/A (p Z 0.038)a NS (use of rescue medications,
p > 0.05)
Usha & Naidu [35] Yes N/A (p < 0.001)a N/A N/A (Pain index, p < 0.001; swelling
index, walking time and join
mobility index, p < 0.05)a
Clegg et al [36] No NS (Pain,
p Z 0.73;
stiffness,
p Z 0.68)
N/A NS (p Z 0.35) N/A NS (use of rescue medications,
joint swelling etc, p > 0.05
Hughes & Carr [37] No NS (p Z 0.54
e0.77)
N/A N/A N/A NS (Global pain, McGill sensory
etc, p > 0.05)
Pavelka et al [38] Yes (p Z 0.01)a (p Z 0.002)a N/A (p Z 0.01)a NS (use of rescue medications,
p > 0.05)
a significant difference between GlcN group and control group.
Efficacy: treatment of GlcN was significantly superior to the placebo in improving the outcome measure(s) stated.
COMPZ serum cartilage oligomeric matrix protein, marker of aggrecan cataboism; CTX-IIZ c-telopeptide of Type II collagen, marker of
type II collagen catabolism; EQ-5D Z European Quality of Life Questionnaire; GlcN Z Glucosamine; N/A Z not applicable; NS Z no
significant difference between GlcN group and control group; OMERACT/OARSI Z Outcome Measure in Rheumatology Clinical Trials/
Osteoarthritis Research Society International; WOMAC Z Western Ontario and McMaster Universities Osteoarthritis.
47glucosamine sulfate is far below the concentration
required for effective uptake of the cell.Efficacy of glucosamine on OA
The outcome measures of OA have generally been focused
on symptomatic, structural, and biochemical changes. GlcN
is said to be “efficacious” towards OA if GlcN treatment was
significantly superior to placebo in improving the outcome
measure(s) (Table 4). Among the articles reviewed, 6
showed that GlcN was effective towards OA or regular
knee pain which included improving the symptoms
[10,33e35,38], preventing joint structural change, [34,38]
and altering cartilage turnover in the subjects [32] when
compared with placebo treatment. The durations of
treatment ranged from 6 weeks to 3 years. For thosereporting positive effects of GlcN on OA, the treatment
would last for more than 12 weeks. Nonetheless, the action
of GlcN on OA-related symptoms could be detected as early
as 2 weeks [21]. It may imply that the present outcome
measures may not be stable and sensitive enough to detect
the changes.
Most of the studies have adopted the WOMAC OA index
as the primary or secondary outcome measures (Table 4).
The WOMAC scale is a questionnaire that measures
dysfunction and pain associated with OA of the lower
extremities and it consists of 3 subscales on pain, stiffness,
and physical functioning [45]. This instrument has been
well studied and found to be reliable and valid [46,47].
However, as patients with OA often take analgesics, the
effects of analgesics may cloud the action of other treat-
ment preparation. Therefore, it is not sufficient to only
measure pain without some objective measures.
Table 5 Outcome measures of animal studies
Study Induced OA
model
Mankin score/OOCHAS Macroscopic cartilage
assessment
GAG content Others
Omegma et al [11] Injection of
protease
(More lesion in protease/GlcN,
p < 0.05)a
N/A (Higher GAG content
in protease/GlcN,
p < 0.01)a
(Higher expression of biglycan in protease/
low GlcN, p < 0.05)a
Lippiello et al [53] ACLT (Less lesion in ACLT/
combination treatment trial
of CS, GlcN, & manganese
ascorbate; p < 0.05)a
N/A NS N/A
Tiraloche et al [54] ACLT (Less lesion in ACLT/GlcN,
p Z 0.049)a
(Lower rate of disease
in the ACLT/GlcN trial
at LTP, p Z 0.046)a
(Higher GAG content
in ACLT/GlcN,
p < 0.05)a
N/A
Wang et al [55] ACLT N/A N/A N/A (Higher osteoid volume in ACLT/GlcN,
p Z 0.041)a
(Higher trabecular bone volume in ACLT/GlcN,
p Z 0.033)a
Chen et al [56] ACLT (Less lesion in ACLT/GlcN,
p < 0.05)a
N/A N/A (Higher expression of TGF-b in ACLT/GlcN,
p < 0.05)a
(Lower expression of IL-1-b in ACLT/GlcN,
p < 0.05)a
Naito et al [57] ACLT NS N/A N/A (Lower CTX-II level in ACLT/GLcN, p < 0.001)a
(Increased CPII level in ACLT/GlcN, p < 0.001)a
Silva et al [58] ACLT (Less cartilage damage in
combination of ACLT/
combination treatment
of GlcN and CS, p < 0.05)a
N/A N/A (Lower pain value in ACLT/combination of GlcN
and CS, p < 0.05)a
Wen et al [59] ACLT (Less lesion in ACLT/GlcN,
p < 0.001)a
(Lower macroscopic
score in ACLT/GlcN,
p Z 0.005)a
N/A (Lower synovitis score in ACLT/GlcN,
p < 0.001)a
(Improved nociceptive behavior in ACLT/GlcN,
p < 0.001)a
(Lower p38 kinase in ACLT/GlcN, p Z 0.002)a
(Lower JNK in ACLT/GlcN, p Z 0.006)a
a significant difference compared with ACLT or protease/control.
ACLT Z anterior cruciate ligament transaction; CP-II Z carboxy propeptide of Type II collagen, marker of Type II collagen synthesis; CTX-II Z Type II collagen C-telopeptide, marker of
Type II collagen catabolism; GAG Z Glycosaminoglycan; GlcN Z Glucosamine; IL-1-b Z interleukin-1- beta; JNK Z c-Jun N-terminal kinase, activated in response to inflammation
cytokines; LTP Z Lateral tibial plateau; N/A Z not applicable; NS Z no significant difference compared with ACLT or enzyme induced/control; OA Z osteoarthritis;
OOCHASZ Osteoarthritis Research Society International (OARSI) Cartilage Histopathology Assessment System; p38 kinaseZ belongs to the family of mitogen-activated protein kinase. It is
activated in response to inflammation cytokines; TGF-b Z transforming growth factor beta.
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49Presently, measurement for the width of joint space is
commonly used as an indirect measure of cartilage repair.
However, the measurement is not sensitive enough as it
often takes 1e2 years before there is reliable information
on the preventive effect of the treatment preparation [48]
and it also has large precision errors [49]. Biochemical
markers could be a more specific outcome measure for
improvement of joint disease. There was a study using
biochemical markers, namely, serum cartilage oligomeric
matrix protein and urine c-telopeptide of Type II collagen
(CTX-II) as indicators of catabolism of aggrecan and Type II
collagen, respectively, and found significant changes in the
serum cartilage oligomeric matrix protein level [32].
Nevertheless, cautions should be paid when interpreting
the data because it is not sure whether the markers level in
blood/urine truly represents the change in joint structure
[48]. Further research is needed to test the reliability of
specific markers and develop more sensitive indicators for
monitoring the disease.
Animal studies
Owing to the slow progress and unclear pathogenesis of OA
[50], human clinical trials have mainly focused on symp-
tomatic relief. The poor sensitivity of the diagnostic tools
and the difficult access to disease tissues also hinder the
research of OA in human [51]. Animal models can therefore
provide an alternative for studying potential antiarthritis
agents.
A Medline search was performed for the years
2000e2010 using the key words “glucosamine”, “in vivo”,
“OA”, and “experimental OA” to screen all citations that
involved oral consumption of GlcN in the management ofTable 6 Glucosamine treatment in animal studies
Study Model Form of
GlcN
Dosage
Omegma et al [11] Injection of CP to
the middle of the
patellar tendon
GlcN HCl 20 mg/k
diet, 10
high Glc
Lippiello et al [53] ACLT, PCLT and
medial meniscus
removed NZ white
rabbits
GlcN HCl 2% by w
GlcN da
Tiraloche et al [54] ACLT, NZ white
rabbits
GlcN HCl 100 mg/
Wang et al [55] ACLT NZ white
rabbits
GlcN HCl 100 mg/
Chen et al [56] ACLT, NZ white
rabbits
GlcN HCl 150 mg/
Naito et al [57] ACLT, Sprague-
Dawley rats
GlcN HCl 1000 mg
Silva et al [58] ACLT male Wistar
rats
GlcN SO4 500 mg/
Wen et al [59] ACLT, Wistar rats GlcN SO4 250 mg/
ACLT Z anterior cruciate ligament transaction; CP Z proteas
PCLT Z posterior cruciate ligament transaction.experimental OA. Studies that compared GlcN-only prepa-
rations with placebo (induced OA control) were included.
There were 8 studies meeting the criteria above (Tables 5
and 6).
Models adopted
The design of animal models on prediction of the effec-
tiveness of a drug should be based on the track record of
predictability of drug induced modification of the disease
progression. Although there are no such agents proven to
modify disease progression of OA [52], most of the models
adopted in testing GlcN were based on the histopatholog-
ical similarities to human disease [50]. For example, ante-
rior cruciate ligament transaction (ACLT) of rabbits [53e56]
and rats [57e59] and enzyme-induced model [11] are
commonly used to study OA. The advantages of these
models include rapid development and reproducible
damage relevant to the traumatic forms of OA [51]. On the
other hand, spontaneous models are better in simulating
the slow progress of the human disease but it usually takes
a long time before observable changes can be recorded
[52]. As yet, there is no consensus on which model and
species are the most relevant for human OA.
Efficacy of glucosamine on change of joint
structures
Histologic/Histochemical Grading System (HHGS, Mankin
score) and the OARSI Cartilage Histopathology Assessment
System are two common methods for analyzing the
progression of cartilage lesions. Both the HHGS and OARSI
Cartilage Histopathology Assessment System have excellentof GlcN Determination of dosage
g/d for low GlcN
0 mg/kg/d for
N diet
Based on the recommended dosage for
human (1.5 g/70 kg/d Z 20 mg/kg/d
approx.)
eight of 500 mg
ily
Not shown
d Based on the recommended dosage for
human (1.5 g/70 kg/d Z 20 mg/kg/d
approx.)
d Not shown
kg/d Not shown
/kg/d Based on a pharmacokinetics study of rat
[64]
kg/d Based on preliminary studies
kg/d Not shown
e-chymopapain; GlcN Z Glucosamine; NZ Z New Zealand;
50 K.O.W. Chan, G.Y.F. Ngintra- and inter-observer reproducibility. The correlation
between the scores is good [60]. (Table 5).
A number of studies have reported that the positive
treatment effect of GlcN would decrease the ACLT induced
cartilage lesion as compared with the ACLT control
[54,56,59]. On the other hand, two of the studies reviewed
showed that combination of GlcN and CS was superior to
GlcN-only treatment in reducing cartilage damage [53,58].
In the study by Tiraloche et al [54], the GlcN group had
a significantly lower rate of disease in the lateral tibial
plateau compartment compared with that of the placebo
group. The less severe cartilage lesion and erosion in tibial
plateau compartment but not the other compartments
implied the site-specificity of GlcN. As suggested by Han-
dley [61], chondrocytes are sensitive to their biomechanical
environment and therefore the metabolic characteristics
are different for weight-bearing and non-weight bearing
regions of articular cartilage.
Although the HHGS was based on study of specimens
with very advanced OA [62], it is valid for normal and
severe OA cartilage, but it does not show a linear rela-
tionship with the change of articular cartilage in mild and
moderate OA [63]. Therefore, caution should be paid on
Oegema’s [11] study, as it used a slightly lower dose of
enzyme to induce a mild OA condition. Contrary to the
studies discussed above [54,56,59], the Mankin score was
significantly higher in GlcN group compared with control,
which indicated more severe damage in the GlcN group.
In studies that measured the cartilage glycosamino-
glycan (GAG) content, controversies were reported. Some
researchers found that the GlcN-treated group had signifi-
cantly preserved the GAG content when compared with the
placebo group [11,54], whereas Lippiello et al [53] could
not find differences in the GAG content between the
ACLT/GlcN and the ACLT/placebo group.
Apart from cartilage, a study had reported significant
reduction in the osteoid volume of the ACLT/GlcN group
compared with that of the ACLT/placebo group [55]. This
finding implied that GlcN treatment has reduced the
subchondral bone changes. Furthermore, based on the
histological assessment, synovial inflammation was less
severe in the ACLT/GlcN group compared with that of
ACLT/placebo group [59].Efficacy of glucosamine on pain relief
Pain is a parameter commonly measured in clinical studies
but not with animal studies because of the question of
validity of measuring pain in animals [51]. In the study by
Silva et al [58], pain was assessed using an articular inca-
pacitation method of the paw elevation time when the sole
was placed on a rotating cylinder to induce painful stimu-
lation to the paw. They found that a combination of GlcN
and CS had significantly reduced the paw elevation time,
but not with the GlcN treatment alone. Wen et al [59]
investigated the nociceptive behaviour of OA rats with
mechanical allodynia and weight-bearing distribution test.
The force required for paw withdrawal in the mechanical
allodynia and the amount of weight shifted to the non-
injured limb were indicators of nociceptive behaviour. They
found that GlcN treatment did reduce pain in the rats.Effect of glucosamine on changes of biochemical
markers
There is substantial interest on the use of biochemical
markers to assess the progress of diseases. It is important to
use biochemical markers in the clinical monitoring for
patients with OA because these markers usually response
rapidly to treatment [48]. Articular cartilage is rich in Type
II collagen and according to the study of Naito et al [57] the
treatment of GlcN would suppress Type II collagen degra-
dation and enhance Type II collagen synthesis in rats with
the ACLT.
Dosage of glucosamine
Most in vivo studies did not determine the Cmax (peak
concentration of a drug observed after its administration)
of GlcN, which may affect the therapeutic relevance of
these studies for human OA [15]. Some studies determined
the dosage based on the recommendation for human of
1.5 g/70 kg BW/d i.e., about 20 mg/kg/d [11,54] (Table 6).
Although GlcN is consumed orally, the absorption efficiency
and metabolism of GlcN may be different among species.
The prediction method used in animal studies could be
used to estimate the effective dosage for a particular
animal model, but the result may not be extrapolated to
human OA. Naito et al [57] had used the dosage of oral GlcN
that achieved comparable serum level with human
according to a pharmacokinetics study of rat. This deter-
mination method was close to the suggestion from Block
et al [15] and it showed better relevance for Human OA.
Conclusion
Based on the results of human clinical trials, half of the
studies reported beneficial effects of GlcN for OA or regular
knee pain. The conflicting results may be because of the
different study design and control of confounding
variables.
Treatment of GlcN for experimental OA has been found
to facilitate cartilage healing, increase cartilage GAG
content, reduce subchondral structural changes, relieve
nociceptive behaviour, and synovitis. However, because
there are large variations in the animal models, GlcN
administration, and outcome measures, the efficacy of
GlcN on different animal models is hard to compare.
Further research is needed to study the validity of these
animal models and the applicability of these models for
human.
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